Medigene AG (FRA:MDG1), a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announces that it has today sold 50% of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. EUR 6.1 million).
The Directors of InvitroCue Limited (ASX:IVQ) are pleased to announce their recently signed Agreement to collaborate with the highly regarded London School of Hygiene & Tropical Medicine.
iQ3Corp Ltd (ASX:IQ3) present their report, together with the financial statements of the Group, being the Company and its controlled entities, for the half-year ended 31 December 2015.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported financial results and operational highlights for the 6 month period ended 31 December 2015.
Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing cell-based therapies to treat unmet medical needs with a focus on osteoarthritis and other musculoskeletal disorders and oncology diseases for both humans and animals.
Vectus Biosystems Ltd (ASX:VBS) has listed on the ASX after raising A$5.1 million through an IPO to continue its search for an effective treatment for fibrosis and high blood pressure.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of a review of safety from the first cohort of 10 patients in the STEP trial.
